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Backgroud. Hereditary angioedema (HAE) is characterized by recurrent swelling of the skin, the abdomen (causing severe acute
pain), and the airways. A recently discovered type caused by mutations in the factor XII gene (designated as HAE type III) occurs
mainlyinwomen.Estrogensmayplayanimportantrole,butfewobstetricalcomplicationshavebeenreported.Case.W er eportthe
symptoms and obstetrical complications of women in two families with HAE attributable to the p. Thr328Lys mutation in the F12
gene. Clinical manifestations included acute and severe maternal abdominal pain, with transient ascites, laryngeal edema, and fetal
and neonatal deaths. Patients had normal C4 levels and a normal C1 inhibitor gene. Administration of C1-inhibitor concentration
twice monthly decreased the attack rate in one mother, and its predelivery administration (1000U) led to the delivery of healthy
girls. Conclusions. Obstetricians and anesthesiologists should be aware of this rare cause of unexplained maternal ascites and in
utero or fetal death associated with edema.
1.Introduction
Hereditary angioedema (HAE), a rare autosomal dominant
disease, manifests as recurrent episodes of localized edema,
which can involve the larynx and lead to upper airway
obstruction and even fatal asphyxiation. Gut involvement
results in occlusion, anorexia, vomiting, abdominal pain,
and ascites. Symptoms usually begin at school age, and
diagnosis is based on a familial history and laboratory data.
In some cases, however, HAE occurs only during pregnancy,
as severe attacks of abdominal pain [1–3]. Moreover, a
normal complement C4 concentration [4]w a sp r e v i o u s l y
considered to rule out HAE. Accordingly, patients without
any positive family history or with normal C4 values [5, 6]
often did not undergo assessment of C1-inhibitor protein
levels and function [7]. The classic forms of HAE, types I
and II, are caused by abnormal C1-inhibitor function, due to
mutations in the gene encoding this inhibitor (SERPING1)
[8, 9]. A third type, initially designated estrogen-dependent
HAE, has recently been described in patients with normal
C1-inhibitor concentration and function. This new type
(called type III HAE) mostly aﬀects women and appears to
be triggered by exposure to high estrogen levels. It may also,
however, occur before puberty, in postmenopausal women,
and, rarely, in men [10–15]. In 2006, Dewald and Bork
identiﬁed the causative mutations in the coagulation factor
XII gene that lead to abnormal kinin generation [16]. In
some families, all aﬀected individuals in some families were2 Obstetrics and Gynecology International
reported to be women, but in others, men were also aﬀected
[11–13, 15]. Although high estrogen levels in these families
may have inﬂuenced the frequency of attacks, exacerbations,
or improvements, few obstetrical complications have been
reported. No miscarriage or fetal or neonatal death was
mentioned in a recent large cohort [15], although Bouillet
et al. did report a case of in utero death in one French family
[17]. We report here obstetrical complications observed in
two families with a missense mutation in the factor XII gene
responsible for recurrent attacks of severe abdominal pain,
transient maternal ascites, and fetal and neonatal deaths in
two carriers from one of the families.
2.Cases
2.1. Family 1. The patient, a 31-year-old Jewish woman,
was followed at our tertiary center during her fourth
pregnancy in a series of complicated pregnancies. During
the ﬁrst, ascites developed at 31 weeks of gestation (WG),
and the fetus died in utero, of an unidentiﬁed cause (no
chromosomal or morphological or placental anomalies).
The simultaneous occurrence of these two events led us
to the conclusion that they were linked. The second and
third pregnancies were very painful, with abdominal attacks
(pains and vomiting) at 10-day intervals. Cesarean deliveries
were performed in both pregnancies, during abdominal
crises with ascites, due to the risk of fetal death, and
led to the birth, at 33 and 35WG, of two healthy girls.
Preeclampsia, antiphospholipid syndrome, thrombophilia,
aﬁbrinogenemia, and factor XIII deﬁciency were all ruled
out. During the last pregnancy, the patient was admitted
on several occasions for vomiting, abdominal pain, and
ultrasound-documented ascites, associated once with acute
kidney injury. Familial Mediterranean fever was ruled out,
both by recurrence during colchicine treatment and by
genetic analysis. At an extensive reinterview, the patient
reported that abdominal symptoms occurred two days after
swelling of the face and extremities, that these symptoms
occurred only during pregnancy or when she used oral
contraception, and generally it resolved within 72 hours.
Testing showed that complement C4- and C1-inhibitor
antigen levels were normal, whereas C1-inhibitor activity,
assessed in an accredited laboratory (VFB) at 30 and 34WG,
was low (33% and 25% of normal values, resp.) (Table 1).
As HAE was suspected, infusion of a C1-inhibitor
concentrate protocol (500U, twice monthly) was initiated.
After three courses of uneventful and eﬃcacious treatment, a
severeabdominalattackwithabundantascitesat35.5WGled
to the infusion of C1-inhibitor concentrate (1000U Berinert
P; CSL Behring, Marburg, Germany) and the extraction
immediatelythereafterofa healthygirl (2500 g).Noepisodes
occurred either after delivery or during the three-year
followup period, and C1-inhibitor function, measured at
month 15, was normal (Table 1).
The patient reported that her maternal grandmother
and a maternal ﬁrst cousin had complained of repeated
episodes of facial swelling. Her mother had reported recur-
rent abdominal pain and vomiting without skin swelling,
both exclusively during pregnancy. This family history is
suggestive of HAE. Two maternal aunts were unaﬀected and
had had normal pregnancies, but a third maternal aunt had
three pregnancies (two boys and twin girls) complicated
by recurrent severe vomiting without skin swelling and
unexplained neonatal deaths. Subsequent testing showed her
to have a normal concentration of functional C1-inhibitor.
One cousin also had recurrent abdominal pains and ascites
during her pregnancy. These clinical presentations lead us to
the diagnosis of type III HAE.
2.2. Family 2. The patient, a 37-year-old Arab woman,
was transferred to our center at 33WG during her second
pregnancy for suspected HAE. She had previously suﬀered
a spontaneous ﬁrst-trimester miscarriage of unknown etiol-
ogy. She complained of edema of the face and larynx and
abdominal pains, all occurring only during pregnancy. Her
mother had died, possibly of laryngeal edema, during her
fourth pregnancy. The patient’s serum C4 component and
C1-inhibitor antigen concentrations were normal, but her
C1-inhibitor activity was 33% of the normal level (Table 1).
The delivery of a healthy girl (4370g) was induced at 41WG
for obstetric reasons after C1-inhibitor perfusion (1000U).
The peripartum period was uneventful, and functional C1-
inhibitor levels reached normal values.
2.3. Genetic Analysis. Blood samples were taken after written
informedconsent.DNAwasextractedandthegeneencoding
complement C1-inhibitor was analyzed and shown to be
normal. We then searched for the recently described p.
Thr328Lys mutation of F12 associated with this type of
HAE. Direct sequencing of forward and reverse strands was
performed with the BigDye terminator cycle sequencing kit
(Applied Biosystems), using the same primers as for PCR
ampliﬁcation (5 -3  F AAGCGCGGAACTGGGGAC; R CCG
GCTGGCCGGAATCTA).
This mutation was identiﬁed in both cases and in the
aﬀected aunt (family 1). Blood samples were not available
from the grandmother, mother, unaﬀected aunts, or cousins
of the ﬁrst case (Figure 1).
3. Discussion
This report establishes a diagnosis of atypical HAE during
pregnancy in two women, based on clinical signs and a
positive family history, despite late onset and normal C4
concentrations, and transient deﬁciencies of C1-inhibitor
function.
Most commonly, the symptoms of HAE due to C1-
inhibitor deﬁciency begin at school age, worsen around
puberty, and are due to mutations resulting in abnormal
C1-inhibitor levels or function, associated with a low serum
C4 concentration [1]. A new type of HAE with normal
C1-inhibitor concentration and function, occurring almost
entirely mostly in women, has been recently described
[10, 11]. The symptoms and course of this type of HAE,
designated as type III HAE, seem to diﬀer from the classic
forms (type I and type II HAE) by its later onset, longer
disease-free intervals, more frequent facial swelling andObstetrics and Gynecology International 3
Table 1: Complement proﬁles in patients. The diagnosis of patient 1 was reviewed two years after the fourth pregnancy. Complement was
quantiﬁed for patient 1 at 30 and 34 weeks of gestation (W) and 15 months after the pregnancy (M15) and for patient 2 at 29 weeks and 33
weeks of gestation and 2 months after the pregnancy (M2). Plasma concentrations of C1 inhibitor (C1 inh), C4, and C3 were determined
by nephelemetry (Dade Behring). Normal values ranged between 170 and 540 mg/L for C1-inhibitor (C1 Inh), 93 and 380 mg/L for C4,
and 660 and 1250 mg/L (±2 SD) for C3. CH50 were determined according to standard procedures. Results are expressed as percent of the
CH50 of the reference plasma pool (obtained from one hundred healthy blood donors). C1-inhibitor function (C1 inh fx) was assessed in a
chromogenic assay (Technochrom, Biolys, Taluyers, France).
Patient 1 Patient 2
Units 30w 34w M15 29w 33w M2
CH50 70–130 % 155 144 131 114 120 107
C3 660–1250 mg/L 1470 1200 989 1270 1310 926
C4 93–380 mg/L 425 352 320 215 257 214
C1 Inh 170–540 mg/L 202 186 239 148 161 190
C1 inh fx 70–130 % 33 25 101 33 35 84
Family 1
Facial swelling
Four unexplained neonatal deaths
In utero death
I∗
II∗
III∗
IV
Several edema during pregnancies
Family 2
Died during pregnancy I∗
II∗
III
(a)
CAG C CCA C / A GACCCGG
Gln Pro Thr Arg
c.1032C>A
p.Thr328Lys
CAG C CCA C / A GACCCGG
Gln Pro Thr Arg
c.1032C>A
p.Thr328Lys
(b)
Figure 1: Mutation in the F12 gene in two pedigrees. The pedigree of the two families is shown. Individuals are identiﬁed by Arabic
numerals within each generation (roman numerals). Aﬀected individuals are indicated with asterisks. A heterozygous mutation was found
in subjects with solid symbols. Electrophoregrams correspond to the DNA sequence surrounding the mutated nucleotide in the F12 gene.
In exon 9, a C > G heterozygous missense mutation was noted in both patients. Direct sequencing of forward and reverse strands was
carried out with the BigDye terminator cycle sequencing kit (Applied Biosystems), using the same primers as for PCR ampliﬁcation (5 -3  F
AAGCGCGGAACTGGGGAC; R CCG GCTGGCCGGAATCTA).
tongue involvement, and less frequent attacks of abdominal
pain[12].Obstetricalcomplicationswerenotreportedinthe
patients in these studies or in those of a large Italian pedigree
[14]. In our patients, HAE was manifested mainly during
pregnancy, the clinical features were transient but recurrent
maternal ascites, abdominal pain, and laryngeal edema. Fetal
and neonatal deaths were observed in two carriers of the F12
gene mutation of one pedigree. To date, only one other in
uterodeath has been described in a woman with HAE caused
by an F12 mutation [17].
We suggest that when ascites occurs during pregnancy
and is due neither to an obstetric cause such as preeclampsia
or mirror syndrome nor to a standard nonobstetric cause,
HAE should be suspected and the patient’s family history
investigated [18]. Screening to conﬁrm suspected cases of
HAE can measure the C4 concentration and C1-inhibitor4 Obstetrics and Gynecology International
antigen levels, but if clinical suspicion is strong, C1-inhibitor
function must be assessed, followed by genetic tests if neces-
sary [7]. Unfortunately these investigations, performed only
in reference laboratories, are time consuming. Furthermore,
although most HAE cases are caused by mutations of the C1-
inhibitor gene, which leads to C1-inhibitor deﬁciency and
low C4 levels (type I or type II HAE), HAE may also occur
in patients with normal C4 levels and normal C1-inhibitor
functions [5, 6, 10–16] and in women with transient C1-
inhibitor deﬁciencies during pregnancy, as in our cases and
another report [17]. When no mutation was detected in our
patients for the gene encoding C1-inhibitor, we searched
for a mutation in the coagulation factor XII gene. In 2006,
Dewald and Bork demonstrated that mutations of this gene
may be related to this novel form of HAE with normal C1-
inhibitor levels and function [16]. The occurrence of this
mutation raises questions about the mechanism underlying
this novel type of HAE, designated as type III. Cichon et
al. suggested that plasma factor XII activity might increase,
while normal factor XII procoagulant levels are maintained
asinourcases(resultsnotshown),andthatthiscouldleadto
increased bradykinin production and vascular permeability
resulting in angioedema. Others, however, could not repli-
cate these results during the symptom-free interval between
attacks [18–21]. Furthermore, the positive regulation of
factor XII gene transcription by estrogens may explain the
strong inﬂuence of estrogens on the disease in some women
[22]. Activation of the kallikrein-kinin system (or contact
system), which induces increased bradykinin formation,
appears to be the main mechanism in the pathophysiology
of the trigger of HAE C1 inhibitor deﬁciency symptoms. If
we consider that the trigger factors are similar in the three
types of HAE, the contact system may be also involved in the
physiopathology of HAE with F12 gene mutations [15, 23].
In clinical practice, HAE diagnosis should be based on
clinicalsymptomsandconﬁrmedbycomplementassessment
and genetic analyses could be limited to cohort studies or
for elucidation of the pathophysiology. Treatment of HAE
during pregnancy presents special problems, particularly
when HAE is clinically suspected and laboratory results are
confusing or not yet available. In cases of a potentially fatal
attack, an infusion of C1-inhibitor concentration (1000–
1500U) should be administered immediately even if the
diagnosis of HAE is only presumptive (at least in the
countries where this treatment is widely available) [4, 7].
Generally, in cases of C1 inhibitor deﬁciency, a positive
responsegenerallyoccurswithintwohoursin95%ofattacks;
if symptoms persist, an additional infusion may be admin-
istered and alternative diagnoses considered [1]. Unfortu-
nately, the eﬃcacy of CI inhibitor concentration for type III
HAEcausedbymutationsintheF12genevariessubstantially
from very to not at all eﬀective [15]. If attacks occur long
before delivery, prophylaxis should be discussed after any
emergency care. Androgens are theoretically contraindicated
and are, in any case, ineﬀective [23]. Tranexamic acid, not
recommended, may trigger thrombotic events [4]. Kallicrein
inhibitor, bradykinin B2 receptor inhibitors (Icatibant), or
recombinant C1-inhibitor may prove useful in the future but
are unlikely to be allowed during pregnancy soon [7, 24, 25].
Currently, for type I and type II HAE, regular C1-inhibitor
replacement therapy can be oﬀered until delivery (once or
t wi c eaw e e k ) ,b u ti ti sd i ﬃcult to predict the requirements of
individual woman [4, 7, 26, 27]. For the peripartum period
of type I or type II HAE, the safest approach appears to be
thesystematicadministrationofapredeliveryinfusionof500
or 1000U of C1 inhibitor concentration [4]. Unfortunately,
no recommendations yet exist for type III HAE. However,
in view of Bouillet’s experience and the eﬃciency of the
administration of 1000U of C1-inhibitor concentration in
the two patients reported here, this predelivery infusion may
be useful during the peripartum period [17]. Furthermore,
because trigger factors appear to be the same as those of
C1 inhibitor deﬁciency, regional analgesia is to be preferred
to endotracheal intubation to avoid laryngeal edema if
operative delivery is undertaken [4, 15].
Obstetricians and physicians should be aware of the
maternal and fetal complications of HAE, a rare disease that
may occur only during pregnancy. It may be suspected on
clinical grounds and may require speciﬁc emergency care or
prophylaxis.
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